BISOPROLOL FUMARATE Drug Patent Profile

When do Bisoprolol Fumarate patents expire, and what generic alternatives are available?

Bisoprolol Fumarate is a drug marketed by Alembic, Aurobindo Pharma, Dash Pharms Natco, Harman Finochem, Novitium Pharma, Prinston Inc, Rubicon, Teva Pharms, Unichem, United Res Labs, Zydus Lifesciences, Actavis Elizabeth, Apothecon, Cadila, Chartwell Rx, Edenbridge Pharms, Epic Pharma Llc, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Mylan, Teva, and Watson Labs Teva. and is included in twenty-four NDAs.

The generic ingredient in BISOPROLOL FUMARATE is bisoprolol fumarate; hydrochlorothiazide. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bisoprolol Fumarate

A generic version of BISOPROLOL FUMARATE was approved as bisoprolol fumarate; hydrochlorothiazide by EPIC PHARMA LLC on September 25^th, 2000.

Summary for BISOPROLOL FUMARATE

US Patents:	0
Applicants:	22
NDAs:	24
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	212
Clinical Trials:	8
Patent Applications:	3,520
Drug Prices:	Drug price information for BISOPROLOL FUMARATE
DailyMed Link:	BISOPROLOL FUMARATE at DailyMed

See drug prices for BISOPROLOL FUMARATE

Recent Clinical Trials for BISOPROLOL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alexandria University	Phase 2
Damanhour University	Phase 2
Laval University	N/A

See all BISOPROLOL FUMARATE clinical trials

Pharmacology for BISOPROLOL FUMARATE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for BISOPROLOL FUMARATE

Adrenergic beta-1 Receptor Antagonists

Antihypertensive Agents

Sympatholytics

Anatomical Therapeutic Chemical (ATC) Classes for BISOPROLOL FUMARATE

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for BISOPROLOL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Pharms Ltd	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	215995-001	Jan 26, 2022	AB	RX	No	No
Chartwell Rx	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075527-001	Sep 25, 2000		DISCN	No	No
Mylan	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075768-003	Sep 25, 2000	AB	RX	No	No
Watson Labs Teva	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075469-002	Sep 25, 2000		DISCN	No	No
Ivax Sub Teva Pharms	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075632-002	Sep 27, 2000		DISCN	No	No
Novitium Pharma	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	215562-001	Nov 4, 2021	AB	RX	No	No
Teva	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075686-003	Jan 19, 2001		DISCN	No	No